Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Most side effects are mild and resolve on their own (injection-site reactions, mild headache, water retention)
In August 2025, Novo Nordisk announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding cirrhosis, in combination with diet and exercise
The subjects received either 1mg of tesamorelin or placebo over 20 weeks and were subsequently measured on their executive function, verbal memory, and visual memory
2021 ESC guidelines on cardiovascular disease prevention in clinical practice
According to the results, taking a GLP-1 (such as Ozempic) for weight loss was associated with a higher risk of pancreatitis, bowel obstruction, and gastroparesis than bupropion-naltrexone
